ArticleEJNMMI research2019
Repeatability of tumor blood flow quantification with
Article in EJNMMI research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Repeatability of tumour perfusion measurement with [EJNMMI research · 2026Article
- Test-retest repeatability of quantitative organ and tissue uptake using 20-minute dynamic multiparametric whole-body [EJNMMI research · 2025Article
- Whole-body parametric mapping of tumour perfusion in metastatic prostate cancer using long axial field-of-view [European journal of nuclear medicine and molecular imaging · 2024Article
- Disrupting NaCancer & metabolism · 2024Article
- Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness.EJNMMI research · 2021Article
- Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and NaEuropean journal of nuclear medicine and molecular imaging · 2021Article
- Slice profile effects on quantitative analysis of hyperpolarized pyruvate.NMR in biomedicine · 2020Article
- Renal Potassium Excretion Visualized onNuclear medicine and molecular imaging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundNon-invasive tumor blood flow (TBF) quantification is a candidate approach for risk stratification and monitoring of prostate cancer patients. Validation data have recently been published on prostate TBF measurement with the widely used positron emission tomography (PET) flow tracer
methodsWe recruited 10 low-to-high-risk prostate cancer patients scheduled for clinical prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) or magnetic resonance imaging. Pelvic and cardiac static and dynamic
resultsFor K1, standardized uptake values (SUV)max, SUVmean, and SUVpeak, prostate cancer
conclusionDynamic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.